Recent Progress in Synthesis and Bioactivity Studies of Heterocyclic Compounds
A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Organic Chemistry".
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 2185
Special Issue Editors
2. Key Laboratory of Nano-Carbon Modified Film Technology Engineering of Henan Province, Xinxiang 453000, China
Interests: cycloadditions; synthesis; heterocycles; biologically active compounds; synthetic methodology
Interests: synthesis; heterocycles; azoles; antibiofilm; sortase A; antimicrobial; anti-inflammatory; ADMETOX; molecular docking
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
In this Special Issue, the aim is to report on recent advances in the use of heterocyclic scaffolds for the development of new bioactive molecules. Heterocyclic compounds play a remarkable role in the field of medicinal chemistry due to their correlation with various pharmacological properties. The molecules of most drugs used in therapy contain heterocyclic systems as active pharmacophores. At the same time, heterocycles could also influence other properties, such as lipophilicity, solubility, stability, and pharmacokinetics.
The multitude of methods available for the synthesis of various heterocycles offers many possibilities for the structural diversification and optimization of biologically active heterocyclic substances.
This Special Issue is dedicated but not limited to the presentation of results concerning the design, synthesis of novel heterocyclic compounds, and in silico/in vitro/in vivo assessment of their biological potential, mechanism of action, ADMETOX, etc.
Dr. Kaikai Wang
Dr. Smaranda Oniga
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- heterocycles
- bioactivity
- synthesis
- molecular docking
- mechanism of action
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
